Trademark: 90138790
Word
AEGLEA
Status
Dead
Status Code
606
Status Date
Monday, June 3, 2024
Serial Number
90138790
Mark Type
4
Filing Date
Wednesday, August 26, 2020
Published for Opposition
Tuesday, September 7, 2021
Abandoned Date
Monday, June 3, 2024

Trademark Owner History
Aeglea BioTherapeutics, Inc. - Owner At Publication

Classifications
5 Pharmaceutical preparations for the treatment of rare genetic diseases; pharmaceutical preparations for the treatment of Arginase 1 deficiency; pharmaceutical preparations for the treatment of cancer; biopharmaceutical preparations for the treatment of rare genetic diseases; biopharmaceutical preparations for the treatment of Arginase 1 deficiency; biopharmaceutical preparations for the treatment of cancer; biotherapeutic preparations for the treatment of rare genetic diseases; biotherapeutic preparations for the treatment of Arginase 1 deficiency; biotherapeutic preparations for the treatment of cancer; biotherapeutic preparations and substances for the treatment of rare genetic diseases; biotherapeutic preparations and substances for the treatment of Arginase 1 deficiency; biotherapeutic preparations and substances for the treatment of cancer; enzyme replacement therapy preparations for medical purposes; pharmaceutical preparations for the prevention and treatment of infectious diseases and immunological diseases; biopharmaceutical preparations for the prevention and treatment of infectious diseases and immunological diseases; pharmaceutical preparations for the treatment of homocystinuria; biopharmaceutical preparations for the treatment of homocystinuria; biotherapeutic preparations for the treatment of homocystinuria
42 Scientific research in the fields of pharmaceuticals, biopharmaceuticals, medicine, biologics, biotherapeutics, biosimilars, enzyme replacement therapeutics, and therapeutics, all for the treatment of rare genetic diseases, Arginase 1 deficiency, cancer, immunological diseases, homocystinuria, and infectious diseases; medical and scientific research in the field of pharmaceutical and biopharmaceutical treatment of rare genetic diseases, Arginase 1 deficiency, cancer, immunological diseases, homocystinuria, and infectious diseases; providing medical and scientific research information, consultancy, and advisory services, all in the fields of pharmaceuticals, biopharmaceuticals, medicine, biologics, biotherapeutics, biosimilars, enzyme replacement therapeutics, and therapeutics treatments, and all for the treatment of rare genetic diseases, Arginase 1 deficiency, cancer, immunological diseases, homocystinuria, and infectious diseases; Design, engineering, research, development and testing services, all for medical research purposes in the fields of cancer, rare genetic disease, Arginase 1 deficiency treatments, immunological diseases, homocystinuria, and infectious diseases

Trademark Events
Aug 29, 2020
New Application Entered
Sep 29, 2020
New Application Office Supplied Data Entered
Jun 29, 2021
Correspondence Received In Law Office
Dec 24, 2020
Assigned To Examiner
Dec 31, 2020
Non-Final Action Written
Dec 31, 2020
Non-Final Action E-Mailed
Dec 31, 2020
Notification Of Non-Final Action E-Mailed
Jun 30, 2021
Teas/Email Correspondence Entered
Jun 29, 2021
Teas Response To Office Action Received
Jul 31, 2021
Approved For Pub - Principal Register
Aug 18, 2021
Notification Of Notice Of Publication E-Mailed
Sep 7, 2021
Published For Opposition
Nov 2, 2021
Noa E-Mailed - Sou Required From Applicant
Sep 7, 2021
Official Gazette Publication Confirmation E-Mailed
Apr 29, 2022
Sou Teas Extension Received
Apr 29, 2022
Sou Extension 1 Filed
Apr 29, 2022
Sou Extension 1 Granted
May 3, 2022
Notice Of Approval Of Extension Request E-Mailed
Nov 1, 2022
Sou Teas Extension Received
Nov 1, 2022
Sou Extension 2 Filed
Nov 1, 2022
Sou Extension 2 Granted
Nov 3, 2022
Notice Of Approval Of Extension Request E-Mailed
May 1, 2023
Sou Extension 3 Filed
May 1, 2023
Sou Extension 3 Granted
May 1, 2023
Sou Teas Extension Received
May 3, 2023
Notice Of Approval Of Extension Request E-Mailed
Nov 2, 2023
Sou Teas Extension Received
Nov 2, 2023
Sou Extension 4 Filed
Nov 2, 2023
Sou Extension 4 Granted
Nov 4, 2023
Notice Of Approval Of Extension Request E-Mailed
May 16, 2024
Assigned To Examiner
Jun 3, 2024
Abandonment - No Use Statement Filed
Jul 12, 2024
Abandonment Notice E-Mailed - No Use Statement Filed

Trademark Alertz updated from USPTO on 2030-01-24